RT Journal Article
SR Electronic
T1 Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.16.21263692
DO 10.1101/2021.09.16.21263692
A1 Yorsaeng, Ritthideach
A1 Suntronwong, Nungruthai
A1 Phowatthanasathian, Harit
A1 Assawakosri, Suvichada
A1 Kanokudom, Sitthichai
A1 Thongmee, Thanunrat
A1 Vichaiwattana, Preeyaporn
A1 Auphimai, Chompoonut
A1 Wongsrisang, Lakkhana
A1 Srimuan, Donchida
A1 Thatsanatorn, Thaksaporn
A1 Klinfueng, Sirapa
A1 Sudhinaraset, Natthinee
A1 Wanlapakorn, Nasamon
A1 Poovorawan, Yong
YR 2021
UL http://medrxiv.org/content/early/2021/09/21/2021.09.16.21263692.abstract
AB In June 2021, Thailand was hit by the delta variant of SARS-CoV-2 resulting in the biggest wave of COVID-19. Due to the widespread delta variant, more than 600 healthcare workers had COVID-19 despite completion of two-dose CoronaVac. The Ministry of Public Health recommended that healthcare workers received a third dose of AZD1222 to increase level of protection against SARS-CoV-2. However, immune response after the third vaccination with AZD1222 are limited. In this study, sera from those who received a booster of AZD1222 in June-July 2021 were tested for SARS-CoV-2 spike receptor-binding-domain (RBD) IgG, anti-RBD total immunoglobulins and anti-spike protein 1 (S1) IgA. The neutralizing activities in a subset of serum samples were tested against the wild type and variants of concern (B.1.1.7, B.1.617.2, and B.1.351) using an enzyme-linked immunosorbent assay-based surrogate virus neutralization test. Participants who received the booster of AZD1222 possessed higher levels of spike RBD-specific IgG, total immunoglobulins, and anti-S1 IgA than that two-dose vaccines (p < 0.001). They also elicited higher neutralizing activity against the wild type and all variants of concern than those in the recipients of the two-dose vaccines. This study demonstrated a high immunogenicity of the AZD1222 booster who completed the two-dose inactivated vaccines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study is registered with the Thai Clinical Trials Registry (TCTR) with identifiers TCTR20210319003 and TCTR20210910002.Funding StatementThis study was funded by the National Research Council of Thailand (NRCT), Health Systems Research Institute (HSRI), MK Restaurant Group, Center of Excellence in Clinical Virology at Chulalongkorn University, and King Chulalongkorn Memorial Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the Institutional Review Board of the Faculty of Medicine of Chulalongkorn University (IRB numbers 192/64 and 546/64).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe availability of all data referred to in the manuscript.